Stryker Co. (NYSE:SYK) Position Lifted by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP raised its holdings in shares of Stryker Co. (NYSE:SYK) by 2.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 828,303 shares of the medical technology company’s stock after purchasing an additional 18,897 shares during the period. Dimensional Fund Advisors LP owned about 0.22% of Stryker worth $298,246,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of SYK. Norges Bank acquired a new position in Stryker during the 4th quarter valued at about $1,710,744,000. Raymond James Financial Inc. acquired a new position in Stryker in the fourth quarter worth approximately $353,394,000. FMR LLC lifted its holdings in shares of Stryker by 10.0% during the fourth quarter. FMR LLC now owns 8,034,844 shares of the medical technology company’s stock valued at $2,892,946,000 after purchasing an additional 727,850 shares during the last quarter. Proficio Capital Partners LLC increased its position in shares of Stryker by 52,520.8% in the fourth quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company’s stock worth $214,660,000 after acquiring an additional 595,061 shares in the last quarter. Finally, APG Asset Management N.V. lifted its holdings in shares of Stryker by 1,695.0% in the fourth quarter. APG Asset Management N.V. now owns 370,226 shares of the medical technology company’s stock valued at $128,730,000 after purchasing an additional 349,601 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. JMP Securities reiterated a “market perform” rating on shares of Stryker in a report on Tuesday, February 18th. The Goldman Sachs Group set a $422.00 price target on shares of Stryker in a research report on Tuesday, March 4th. Royal Bank of Canada raised their price objective on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Finally, Canaccord Genuity Group boosted their price target on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $423.53.

Stryker Stock Down 0.1 %

Shares of NYSE:SYK opened at $346.46 on Monday. The company has a 50 day moving average of $370.95 and a 200-day moving average of $373.31. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The stock has a market cap of $132.24 billion, a price-to-earnings ratio of 44.65, a P/E/G ratio of 2.93 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the business earned $3.46 EPS. On average, sell-side analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.97%. Stryker’s dividend payout ratio is presently 43.30%.

Insider Buying and Selling at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.